Intellia Therapeutics, Inc. (NTLA)
NASDAQ: NTLA · Real-Time Price · USD
9.25
-0.05 (-0.54%)
Dec 10, 2025, 1:36 PM EST - Market open

Intellia Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 20202015 - 2019
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
1,0711,1882,7312,9748,7993,514
Upgrade
Market Cap Growth
-23.77%-56.51%-8.18%-66.20%150.41%390.02%
Upgrade
Enterprise Value
4963441,8562,2237,7273,128
Upgrade
Last Close Price
9.3011.6630.4934.89118.2454.40
Upgrade
PS Ratio
16.9520.5275.2757.06266.2260.59
Upgrade
PB Ratio
1.441.362.602.418.466.67
Upgrade
P/TBV Ratio
1.431.362.602.418.466.67
Upgrade
EV/Sales Ratio
8.625.9551.1742.65233.7653.94
Upgrade
Debt / Equity Ratio
0.130.240.110.110.070.08
Upgrade
Asset Turnover
0.060.050.030.040.030.12
Upgrade
Quick Ratio
5.575.508.239.455.979.33
Upgrade
Current Ratio
6.215.778.669.626.119.60
Upgrade
Return on Equity (ROE)
-52.11%-54.01%-42.10%-41.67%-34.19%-33.69%
Upgrade
Return on Assets (ROA)
-28.51%-26.80%-22.83%-20.35%-16.99%-16.89%
Upgrade
Return on Capital (ROIC)
-31.32%-29.71%-25.44%-23.09%-19.92%-19.98%
Upgrade
Return on Capital Employed (ROCE)
-57.60%-49.50%-43.50%-32.90%-22.90%-22.30%
Upgrade
Earnings Yield
-41.74%-43.70%-17.62%-15.95%-3.04%-3.82%
Upgrade
FCF Yield
-38.64%-29.87%-14.95%-11.66%-2.70%-1.52%
Upgrade
Buyback Yield / Dilution
-9.22%-11.35%-15.33%-8.57%-26.63%-18.50%
Upgrade
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q